The anti-tumor effects of entinostat in ovarian cancer require adaptive immunity

BACKGROUND: Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in ovarian cancer patients. We previously demonstrated that the histone deacetylase inhibitor entinostat i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Smith, Haller J., McCaw, Tyler R., Londono, Angelina I., Katre, Ashwini A., Meza-Perez, Selene, Yang, Eddy S., Forero, Andres, Buchsbaum, Donald J., Randall, Troy D., Straughn, J. Michael, Norian, Lyse A., Arend, Rebecca C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6294677/
https://ncbi.nlm.nih.gov/pubmed/30423192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31761
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados